Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures - PubMed
2 days ago
- #Microbiome
- #Cancer Treatment
- #Immunotherapy
- Proton pump inhibitors (PPIs) are widely used and linked to altered gut microbiome, affecting immune checkpoint inhibitor (ICI) response.
- PPI use is associated with shorter overall survival (OS) in advanced cancer patients treated with ICIs, especially in melanoma.
- The study analyzed stool and blood samples from melanoma, NSCLC, and renal cell carcinoma patients to assess microbiome and immune cell changes.
- Findings suggest PPI use may negatively impact immunotherapy efficacy through microbiome alterations.
- The research highlights the importance of considering microbiome and concomitant medications in cancer treatment strategies.